Save the Date: Registration to Open in 2024
Saturday, May 11, 2024 | 8:30AM – 3PM
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this in-person education program is designed to focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, updates, and new categories in the 5th Edition of the World Health Organization Classification of Hematolympoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition-Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi-will discuss notable updates, modications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice. As usual, there will be case-based podium presentations followed by discussion. A poster session will also take place.
Reza Nejati, MD
Medical Director of TUHS-FCCC Clinical Laboratories
Director, Flow Cytometry Lab
Department of Pathology
Fox Chase Cancer Center
Joseph Khoury, MD
Professor & Chair,
Department of Pathology and Microbiology
University of Nebraska Medical Center
German Ott, MD
Professor and Head
Department of Clinical Pathology
DISTINGUISHED GUEST SPEAKER
Sanam Loghavi, MD
Department of Hematopathology
MD Anderson Cancer Center
Lucía Tono, PhD, MEd: 215-728-3797
Hematopathologists, pathologists of other subspecialties, hematologists/oncologists, radiation oncologists, internists, primary care providers, fellows and residents of pathology, oncology and other specialties.
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.
It is the policy of Fox Chase Cancer Center, that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.